Ladenburg Thalmann Financial Services began coverage on shares of BeiGene, Ltd. (NASDAQ:BGNE) in a research report report published on Monday, Marketbeat reports. The brokerage issued a buy rating and a $81.00 price target on the stock.

Several other equities analysts also recently commented on BGNE. Maxim Group set a $57.00 target price on BeiGene and gave the stock a buy rating in a research report on Saturday, July 1st. Robert W. Baird raised their target price on BeiGene from $44.00 to $58.00 and gave the stock an outperform rating in a research report on Thursday, July 6th. Morgan Stanley restated an overweight rating and set a $83.00 target price on shares of BeiGene in a research report on Monday, July 10th. Zacks Investment Research upgraded BeiGene from a sell rating to a buy rating and set a $79.00 target price for the company in a research report on Tuesday, July 11th. Finally, William Blair restated an outperform rating on shares of BeiGene in a research report on Thursday, June 1st. Seven analysts have rated the stock with a buy rating, The stock has an average rating of Buy and an average price target of $74.80.

Shares of BeiGene (NASDAQ BGNE) opened at 77.30 on Monday. BeiGene has a 12-month low of $26.43 and a 12-month high of $79.89. The firm’s market cap is $3.07 billion. The firm has a 50-day moving average price of $65.71 and a 200-day moving average price of $45.09.

TRADEMARK VIOLATION WARNING: “BeiGene, Ltd. (NASDAQ:BGNE) Research Coverage Started at Ladenburg Thalmann Financial Services” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/10/beigene-ltd-nasdaqbgne-research-coverage-started-at-ladenburg-thalmann-financial-services.html.

In other news, CEO John Oyler sold 98,500 shares of BeiGene stock in a transaction on Friday, June 23rd. The stock was sold at an average price of $44.16, for a total value of $4,349,760.00. Following the completion of the sale, the chief executive officer now directly owns 88,535 shares of the company’s stock, valued at approximately $3,909,705.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Xiaodong Wang sold 5,539 shares of BeiGene stock in a transaction on Friday, June 2nd. The shares were sold at an average price of $40.00, for a total value of $221,560.00. Following the completion of the sale, the director now directly owns 55,000 shares of the company’s stock, valued at $2,200,000. The disclosure for this sale can be found here. In the last quarter, insiders sold 389,249 shares of company stock valued at $22,594,820. Corporate insiders own 24.20% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC purchased a new stake in BeiGene during the second quarter valued at approximately $111,000. Renaissance Technologies LLC bought a new stake in shares of BeiGene during the first quarter worth approximately $238,000. Airain ltd bought a new stake in shares of BeiGene during the first quarter worth approximately $320,000. ProShare Advisors LLC boosted its stake in shares of BeiGene by 42.0% in the first quarter. ProShare Advisors LLC now owns 9,872 shares of the company’s stock worth $361,000 after buying an additional 2,918 shares during the period. Finally, Parametric Portfolio Associates LLC boosted its stake in shares of BeiGene by 59.1% in the first quarter. Parametric Portfolio Associates LLC now owns 10,796 shares of the company’s stock worth $395,000 after buying an additional 4,010 shares during the period. 43.85% of the stock is owned by institutional investors.

BeiGene Company Profile

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.

Analyst Recommendations for BeiGene (NASDAQ:BGNE)

Receive News & Stock Ratings for BeiGene Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene Ltd. and related stocks with our FREE daily email newsletter.